These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

588 related articles for article (PubMed ID: 32097925)

  • 21. Easy clinical predictor for low BCAA to tyrosine ratio in chronic liver disease patients with hepatocellular carcinoma: Usefulness of ALBI score as nutritional prognostic marker.
    Hiraoka A; Kato M; Marui K; Murakami T; Onishi K; Adachi T; Matsuoka J; Ueki H; Yoshino T; Tsuruta M; Aibiki T; Okudaira T; Kuroda T; Iwasaki R; Suga Y; Miyata H; Ninomiya T; Hirooka M; Abe M; Matsuura B; Michitaka K; Hiasa Y
    Cancer Med; 2021 Jun; 10(11):3584-3592. PubMed ID: 33960691
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Post-Progression Treatment Eligibility of Unresectable Hepatocellular Carcinoma Patients Treated with Lenvatinib.
    Hiraoka A; Kumada T; Fukunishi S; Atsukawa M; Hirooka M; Tsuji K; Ishikawa T; Takaguchi K; Kariyama K; Itobayashi E; Tajiri K; Shimada N; Shibata H; Ochi H; Tada T; Toyoda H; Yokohama K; Nouso K; Tsutsui A; Nagano T; Itokawa N; Hayama K; Arai T; Imai M; Joko K; Koizumi Y; Hiasa Y; Michitaka K; Kudo M
    Liver Cancer; 2020 Jan; 9(1):73-83. PubMed ID: 32071911
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Liver function assessment according to the Albumin-Bilirubin (ALBI) grade in sorafenib-treated patients with advanced hepatocellular carcinoma.
    Ogasawara S; Chiba T; Ooka Y; Suzuki E; Kanogawa N; Saito T; Motoyama T; Tawada A; Kanai F; Yokosuka O
    Invest New Drugs; 2015 Dec; 33(6):1257-62. PubMed ID: 26462681
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Independent Analysis of Albumin-Bilirubin Grade in a 765-Patient Cohort Treated with Transarterial Locoregional Therapy for Hepatocellular Carcinoma.
    Hickey R; Mouli S; Kulik L; Desai K; Thornburg B; Ganger D; Baker T; Abecassis M; Ralph Kallini J; Gabr A; Gates VL; Benson Iii AB; Lewandowski RJ; Salem R
    J Vasc Interv Radiol; 2016 Jun; 27(6):795-802. PubMed ID: 27038686
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Change in arterial tumor perfusion is an early biomarker of lenvatinib efficacy in patients with unresectable hepatocellular carcinoma.
    Kuorda H; Abe T; Fujiwara Y; Okamoto T; Yonezawa M; Sato H; Endo K; Oikawa T; Sawara K; Takikawa Y
    World J Gastroenterol; 2019 May; 25(19):2365-2372. PubMed ID: 31148907
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Liver Function in Older Patients With Unresectable Hepatocellular Carcinoma After Administration of Lenvatinib.
    Sasaki R; Fukushima M; Haraguchi M; Miuma S; Miyaaki H; Hidaka M; Eguchi S; Matsuo S; Matsuzaki T; Hashimoto S; Ohba K; Kugiyama Y; Yatsuhashi H; Shibata H; Motoyoshi Y; Shigeno M; Iwatsu S; Kato Y; Kinoshita N; Nakao K
    Anticancer Res; 2021 Apr; 41(4):2025-2032. PubMed ID: 33813409
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Albumin-Bilirubin and Platelet-Albumin-Bilirubin Grades Accurately Predict Overall Survival in High-Risk Patients Undergoing Conventional Transarterial Chemoembolization for Hepatocellular Carcinoma.
    Hansmann J; Evers MJ; Bui JT; Lokken RP; Lipnik AJ; Gaba RC; Ray CE
    J Vasc Interv Radiol; 2017 Sep; 28(9):1224-1231.e2. PubMed ID: 28688815
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Efficacy of lenvatinib for unresectable hepatocellular carcinoma based on background liver disease etiology: multi-center retrospective study.
    Hiraoka A; Kumada T; Tada T; Tani J; Kariyama K; Fukunishi S; Atsukawa M; Hirooka M; Tsuji K; Ishikawa T; Takaguchi K; Itobayashi E; Tajiri K; Shimada N; Shibata H; Ochi H; Kawata K; Yasuda S; Toyoda H; Aoki T; Tanaka T; Ohama H; Nouso K; Tsutsui A; Nagano T; Itokawa N; Arai T; Okubo T; Imai M; Koizumi Y; Nakamura S; Joko K; Hiasa Y; Kudo M;
    Sci Rep; 2021 Aug; 11(1):16663. PubMed ID: 34404856
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Albumin-Bilirubin grade predicts prognosis of HCC patients with sorafenib use.
    Kuo YH; Wang JH; Hung CH; Rau KM; Wu IP; Chen CH; Kee KM; Hu TH; Lu SN
    J Gastroenterol Hepatol; 2017 Dec; 32(12):1975-1981. PubMed ID: 28295594
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Real-world effectiveness of lenvatinib monotherapy among unresectable hepatocellular carcinoma patients in the USA.
    Singal AG; Nagar SP; Hitchens A; Davis KL; Iyer S
    Future Oncol; 2021 Jul; 17(21):2759-2768. PubMed ID: 33832339
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Comparison of Modified Child-pugh (MCP), Albumin-bilirubin (ALBI), and Child-pugh (CP) score for predicting of survival in Hepatocellular Carcinoma Patients Treated with Transcatheter Arterial Chemoembolization.
    Liu Y; Cheng C; Zhou H; Hu S; Wang H; Xie Q; Lei L; Wang P; Liu G; Hu H
    Bull Cancer; 2021 Oct; 108(10):931-939. PubMed ID: 34247763
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Assessment of the Albumin-Bilirubin (ALBI) Grade as a Prognostic Indicator for Hepatocellular Carcinoma Patients Treated With Radioembolization.
    Gui B; Weiner AA; Nosher J; Lu SE; Foltz GM; Hasan O; Kim SK; Gendel V; Mani NB; Carpizo DR; Saad NE; Kennedy TJ; Zuckerman DA; Olsen JR; Parikh PJ; Jabbour SK
    Am J Clin Oncol; 2018 Sep; 41(9):861-866. PubMed ID: 28418940
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Onodera's prognostic nutritional index is a strong prognostic indicator for patients with hepatocellular carcinoma after initial hepatectomy, especially patients with preserved liver function.
    Tanemura A; Mizuno S; Hayasaki A; Gyoten K; Fujii T; Iizawa Y; Kato H; Murata Y; Kuriyama N; Kishiwada M; Sakurai H; Isaji S
    BMC Surg; 2020 Oct; 20(1):261. PubMed ID: 33129309
    [TBL] [Abstract][Full Text] [Related]  

  • 34. ALBI Grade Is a Predictive Factor of Lenvatinib Treatment Discontinuation due to Adverse Events in Hepatocellular Carcinoma.
    Enomoto D; Yamamoto K; Matsumoto Y; Morioka A; Omura T; Komatsu S; Yano Y; Fukumoto T; Yano I
    Anticancer Res; 2023 Mar; 43(3):1317-1323. PubMed ID: 36854508
    [TBL] [Abstract][Full Text] [Related]  

  • 35. ALBI versus Child-Pugh grading systems for liver function in patients with hepatocellular carcinoma.
    Na SK; Yim SY; Suh SJ; Jung YK; Kim JH; Seo YS; Yim HJ; Yeon JE; Byun KS; Um SH
    J Surg Oncol; 2018 Apr; 117(5):912-921. PubMed ID: 29448306
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Phase 2 study of lenvatinib in patients with advanced hepatocellular carcinoma.
    Ikeda K; Kudo M; Kawazoe S; Osaki Y; Ikeda M; Okusaka T; Tamai T; Suzuki T; Hisai T; Hayato S; Okita K; Kumada H
    J Gastroenterol; 2017 Apr; 52(4):512-519. PubMed ID: 27704266
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Lenvatinib plus pembrolizumab for systemic therapy-naïve and -experienced unresectable hepatocellular carcinoma.
    Wu CJ; Lee PC; Hung YW; Lee CJ; Chi CT; Lee IC; Hou MC; Huang YH
    Cancer Immunol Immunother; 2022 Nov; 71(11):2631-2643. PubMed ID: 35347395
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Subsequent locoregional therapy prolongs survival in progressive hepatocellular carcinoma patients under lenvatinib treatment.
    Lin PT; Teng W; Jeng WJ; Lin CC; Lin CY; Lin SM; Sheen IS
    J Formos Med Assoc; 2024 Jul; 123(7):788-795. PubMed ID: 38310071
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Lenvatinib versus sorafenib for first-line treatment of unresectable hepatocellular carcinoma: patient-reported outcomes from a randomised, open-label, non-inferiority, phase 3 trial.
    Vogel A; Qin S; Kudo M; Su Y; Hudgens S; Yamashita T; Yoon JH; Fartoux L; Simon K; López C; Sung M; Mody K; Ohtsuka T; Tamai T; Bennett L; Meier G; Breder V
    Lancet Gastroenterol Hepatol; 2021 Aug; 6(8):649-658. PubMed ID: 34087115
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Modified Albumin-Bilirubin Model for Stratifying Survival in Patients with Hepatocellular Carcinoma Receiving Anticancer Therapy.
    Hsu WF; Hsu SC; Chen TH; Lin CH; Lin YC; Chang YW; Wang HW; Liao YM; Lai HC; Peng CY
    Cancers (Basel); 2022 Oct; 14(20):. PubMed ID: 36291867
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 30.